Comprehensive Discussions on GLP-1 RAs and SGLT2 Inhibitors

Dear Dr. Renukaprasad A R, Although GLP-1 RAs and SGLT2 inhibitors reduce glucose levels, body weight, and the risk of diabetes-related complications, they have differences in providing benefits and causing adverse events. Therefore, diabetologists must be aware of their characteristics before prescribing them to their patients. Unlike other GLP-1 RAs, semaglutide has a longer half-life and can be administered subcutaneously or orally. Compared to other GLP-1 RAs, semaglutide is found to cause no major adverse events except for increasing cholelithiasis risk and causing mild gastrointestinal disturbances. However, several clinical trials are going on to improve the use of semaglutide. To make your diabetes management strategy efficient with GLP-1 RAs and SGLT2 inhibitors, we exclusively bring you a special Global Diabetes Summit 2023 session by leading Diabetologists Dr. Kathija Mahmood and Dr. Supratik Bhattacharya TODAY from 3:00 PM IST onwards. Topics - Assessing the Comparative Effectiveness of GLP-1 Receptor Agonists vs. SGLT2 Inhibitors in Type 2 Diabetes – Dr. Kathija Mahmood Efficacy and Safety of Semaglutide in Type 2 Diabetes – Dr. Supratik Bhattacharya Join Now Docplexus: One of the world's largest online communities of Doctors Pune - 411045, India info@docplexus.co.in   |  +91 98500 36954 You are receiving this communication because you are registered member of Docplexus. Unsubscribe from this mailing list. *|LIST:DESCRIPTION|* *|LIST:ADDRESS|* *|REWARDS_TEXT|*